Journals / Turkish Journal of Pharmaceutical Sciences / 2021 / Cilt: 18 - Sayı: 5

Nanoemulsions as Ophthalmic Drug Delivery Systems

Oftalmik İlaç Taşıyıcı Sistemler Olarak Nanoemülsiyonlar

Pages
135–145
Publication Date
2022-11-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review article summarizes the main characteristics of nanoemulsions, ophthalmic nanoemulsions, and cationic nanoemulsions and their components, methods of preparation, and the evaluation parameters for ophthalmic nanoemulsions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nanoemulsions are liquid-in-liquid dispersion with a droplet size of about 100 nm.
📊
Key Findings & Data:They have a transparent appearance, high rate of bioavailability, and increased shelf life.
💡
Conclusion & Impact:This review article summarizes the main characteristics of nanoemulsions, ophthalmic nanoemulsions, and cationic nanoemulsions and their components, methods of preparation, and the evaluation parameters for ophthalmic nanoemulsions.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Nanoemulsions are liquid-in-liquid dispersion with a droplet size of about 100 nm. They have a transparent appearance, high rate of bioavailability, and increased shelf life. Nanoemulsions mainly consist of oil, water, surfactant, and cosurfactant and can be prepared by high- and low-energy methods. Diluted nanoemulsions are utilized for the delivery of ophthalmic drugs due to their capability to penetrate the deep layers of the ocular structure, provide a sustained release effect, and reduce the frequency of administration and side effects. These nanoemulsions are subjected to certain tests, such as safety, stability, pH profile, rheological studies, and so on. Cationic nanoemulsions are prepared for topical ophthalmic delivery of active ingredients from cationic agents to increase the drug residence time on the ocular surface, reducing their clearance from the ocular surface and improving drug bioavailability. This review article summarizes the main characteristics of nanoemulsions, ophthalmic nanoemulsions, and cationic nanoemulsions and their components, methods of preparation, and the evaluation parameters for ophthalmic nanoemulsions.

Özet

Nanoemülsiyonlar, yaklaşık 100 nm’lik bir damlacık boyutuna sahip sıvı içinde sıvı dispersiyonudur. Şeffaf bir görünüme, yüksek biyoyararlanıma ve artırılmış raf ömrüne sahiptirler. Nanoemülsiyonlar esas olarak yağ, su, yüzey aktif madde ve yardımcı yüzey aktif maddeden oluşur ve yüksek ve düşük enerjili yöntemlerle hazırlanabilir. Seyreltilmiş nanoemülsiyonlar, oküler yapının derin katmanlarına nüfuz etme, sürekli salım etkisi sağlama ve uygulama sıklığını ve yan etkileri azaltma kabiliyetleri nedeniyle oftalmik ilaçların verilmesi için kullanılır. Bu nanoemülsiyonlar, güvenlik, stabilite, pH profili, reolojik çalışmalar vb. gibi belirli testlere tabi tutulur. Katyonik nanoemülsiyonlar, ilacın oküler yüzey üzerinde kalış süresini artırmak, oküler yüzeyden klirensini azaltmak ve ilaç biyoyararlanımını geliştirmek için katyonik ajanlardan aktif bileşenlerin topikal olarak oftalmik taşınımı için hazırlanır. Bu derleme, nanoemülsiyonların, oftalmik nanoemülsiyonların ve katyonik nanoemülsiyonların temel özelliklerini ve bileşenlerini, hazırlama yöntemlerini ve oftalmik nanoemülsiyonlar için değerlendirme parametrelerini özetlemektedir.

🔖

Cite This Article

DHAHIR, R. K., AL-NIMA, A. M., AL-BAZZAZ, F. Y. (2022). Nanoemulsions as Ophthalmic Drug Delivery Systems. Turkish Journal of Pharmaceutical Sciences, Cilt: 18 - Sayı: 5, 135–145. https://ajindex.com/articles/613620

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Bucolo C, Drago F, Salomone S. Ocular drug delivery: a clue from nanotechnology. Front Pharmacol. 2012;3:1-3
  2. Al-bazzaz FY, Al-kotaji M. Ophthalmic in-situ sustained gel of ciprofloxacin, preparation and evaluation study. Int J Appl Pharm. 2018;10:153-161
  3. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech. 2009;10:808-819
  4. Kumari A, Sharma PK, Garg VK, Garg G. Ocular inserts: advancement in therapy of eye diseases. J Adv Pharm Technol Res. 2010;1:291-296
  5. Lallemand F, Daull P, Benita S, Buggage R, Garrigue JS. Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb. J Drug Deliv. 2012;2012:604204
  6. Shah J, Nair A, Jacob S, Patel R, Shah H, Shehata T, Morsy M. Nanoemulsion based vehicle for effective ocular delivery of moxifloxacin using experimental design and pharmacokinetic study in rabbits. Pharmaceutics. 2019;11:230
  7. SCCS. “Guidance on the safety assessment of nanomaterials in cosmetics”(2012). Avaialable from: https://ec.europa.eu/newsroom/ sante/items/661871 8. Yen CC, Chen YC, Wu MT, Wang CC, Wu YT. Nanoemulsion as a strategy for improving the oral bioavailability and antiinflammatory activity of andrographolide. Int J Nanomedicine. 2018;13:669-680
  8. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol. 2013;2:47-64
  9. Huang D, Chen YS, Rupenthal ID. Overcoming ocular drug delivery barriers through the use of physical forces. Adv Drug Deliv Rev. 2018;126:96-112
  10. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12:348-360
  11. Suri R, Beg S, Kohli K. Target strategies for drug delivery bypassing ocular barriers. J Drug Deliv Sci Technol. 2020;55:101389
  12. Singh V, Ahmad R, Heming T. The challenges of ophthalmic drug delivery: a review. Int J Drug Discov. 2011;3:56-62
  13. Agban Y, Thakur SS, Mugisho OO, Rupenthal ID. Depot formulations to sustain periocular drug delivery to the posterior eye segment. Drug Discov Today. 2019;24:1458-1469
  14. DeGorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 2012;52:249-273
  15. Ruponen M, Urtti A. Undefined role of mucus as a barrier in ocular drug delivery. Eur J Pharm Biopharm. 2015;96:442-446
  16. D’Emanuele A, Jevprasesphant R, Penny J, Attwood D. The use of a dendrimer-propranolol prodrug to bypass efflux transpor